JJ
Therapeutic Areas
Cocrystal Pharma Pipeline
| Drug | Indication | Phase |
|---|---|---|
| CC-42344 (Oral PB2 inhibitor) | Influenza A | Phase 2 |
| CC-42344 (Inhaled PB2 inhibitor) | Influenza A | Phase 1 |
| CDI-988 (Oral Pan-viral protease inhibitor) | Norovirus | Phase 1 |
| Pan-viral protease inhibitor | Rhinovirus | Discovery/Preclinical |
| Oral replication inhibitor | Influenza A & B | Discovery/Preclinical |
Leadership Team at Cocrystal Pharma
SL
Sam Lee, Ph.D.
Co-Chief Executive Officer and President
RK
Roger Kornberg, Ph.D.
Chairman of the Board, Chief Scientist and Chairman of Scientific Advisory Board
SR
Steve Rubin
Vice Chairman of the Board
PF
Phillip Frost, M.D.
Director
FH
Fred Hassan
Director